Extended Data Table 8 Deaths due to adverse events

From: Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial

  1. Safety analysis set included patients who received ≥1 dose of study treatment. AEs defined as any AE newly occurring or worsening after the first dose of study treatment to 18 weeks after last dose of study treatment. MedDRA Dictionary (version 24.0) was used for coding AEs.
  2. GVHD, graft-versus-host disease.
  3. * Deaths due to adverse events (AEs) occurring during the safety analysis period from first dose of study treatment to 18 weeks after last dose of study treatment.
  4. † Deaths due to AEs occurring in the time period after 18 weeks from the last dose of study treatment.
Back to article page